Bextra Recall

On April 7, 2005, the U.S. Food and Drug Administration (FDA) asked Pfizer, Inc., the world's largest drug maker, to cease marketing and selling Bextra (Valdexoib) in the U.S. The FDA determined the overall risk versus benefit ratio of Bextra was unfavorable. Bextra is an anti-inflammatory and pain killer used by arthritis sufferers. The primary reason for the decision to pull Bextra from the market was an increase in the risk of cardiovascular problems, including strokes, and serious skin reactions.

In addition to the recent withdrawl of Bextra, the FDA is requiring new warning labels be included for other non-steroid anti-inflammatory drugs (NSAIDS) such as Celebrex, another drug manufactured by Pfizer, Inc. Researchers believe this drug class may impede the ability for the body to reduce blood clots.

On April 7, Pfizer stated “Patients should stop taking Bextra and contact their physician to discuss alternate treatments."

If you or a loved one have taken Bextra and have experienced side effects including, cardiovascular, gastrointestinal bleeding, or skin problems, contact our office right away at 1-888-393-2029 or email us. You may have a claim for the physical harm you have suffered.

Please do not discontinue taking any medications
without first consulting your doctor

ADDITIONAL INFORMATION:
FDA Press Release - April 7, 2005
http://www.fda.gov/bbs/topics/news/2005/NEW01171.html
FDA Public Health Advisory
http://www.fda.gov/cder/drug/advisory/COX2.htm
COX-2 Selective and NSAIDS Drugs
http://www.fda.gov/cder/drug/infopage/cox2/default.htm
Questions and Answers - FDA Regulatory Actions for the COX-2 Selective and NSAIDs
http://www.fda.gov/cder/drug/infopage/COX2/COX2qa.htm
Refund Information for Unused Tablets
http://www.bextra.com/

RECENT NEWS STORIES:

ABC News: